Frequency of Hepatitis C in Patients with Chronic Kidney Disease Undergoing Hemodialysis
Article Sidebar
Main Article Content
Abstract
Objective: To determine the frequency of HCV in patients with CKD undergoing hemodialysis.
Methods: This cross-sectional study, conducted from May 12, 2023, to November 12, 2023, included 172 patients with CKD stage V on hemodialysis for at least 3 months. Blood samples were tested for HCV antibodies using enzyme immunoassay (EIA) and confirmed with HCV-RNA polymerase chain reaction (PCR). Data on age, gender, body mass index (BMI), duration of CKD, hemodialysis duration, and comorbidities were analyzed using SPSS version 22.
Results: Among 172 patients (mean age 45 ± 12.29 years; 53% male), 53 (31%) tested positive for HCV. No significant associations were found between HCV status and age, gender, BMI, CKD duration, hemodialysis duration, diabetes, hypertension, or coronary artery disease (P > 0.05).
Conclusion: The frequency of HCV in hemodialysis patients at Ayub Teaching Hospital was 31%, highlighting a significant public health burden. Targeted screening and infection control measures are essential.
Article Details
Work published in JPMI is licensed under a
Creative Commons Attribution-NonCommercial 2.0 Generic License.
Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
References
1. Saadi G, Kalantar-Zadeh K, Almasio P, Ashuntantang G, Barsoum R, Bruchfeld A, et al. Hepatitis C virus infection and global kidney health: the consensus proceedings of the International Federation of Kidney Foundations. Afr J Nephrol 2020;23(1):159-68. DOI: 10.21804/23-1-4210.
2. Al Kanaani Z, Mahmud S, Kouyoumjian SP, Abu-Raddad LJ. The epidemiology of hepatitis C virus in Pakistan: systematic review and meta-analyses. R Soc Open Sci 2018;5(4):180257. DOI: 10.1098/rsos.180257.
3. Hasan M, Sutradhar I, Gupta RD, Sarker M. Prevalence of chronic kidney disease in South Asia: a systematic review. BMC Nephrol 2018;19(1):291. DOI: 10.1186/s12882-018-1072-5.
4. Fabrizi F, Messa P. The epidemiology of HCV infection in patients with advanced CKD/ESRD: a global perspective. Semin Dial 2019;32(2):93-8. DOI: 10.1111/sdi.12757.
5. Butt N, Abbasi A, Ali Khan M, et al. Treatment outcomes for patients undergoing hemodialysis with chronic hepatitis C on the sofosbuvir and daclatasvir regimen. Cureus 2019;11(9):e5702. DOI: 10.7759/cureus.5702.
6. Akhtar S, Nasir JA, Usman M, et al. The prevalence of hepatitis C virus in hemodialysis patients in Pakistan: a systematic review and meta-analysis. PLoS One 2020;15(5):e0232931. DOI: 10.1371/journal.pone.0232931.
7. Fissell RB, Bragg-Gresham JL, Woods JD, Jadoul M, Gillespie B, Hedderwick SA, et al. Patterns of hepatitis C prevalence and seroconversion in hemodialysis units from three continents: the DOPPS study. Kidney Int 2004;65(6):2335-42. DOI: 10.1111/j.1523-1755.2004.00649.x.
8. Shafi ST, Hassan MZ, Saleem M, et al. Frequency of hepatitis C in hospitalized patients with chronic kidney disease. Pak J Med Sci 2017;33(1):18-21. DOI: 10.12669/pjms.331.11553.
9. Elahi W, Syed AZ, Nasim F, et al. Hepatitis B and C infections in patients with prolonged hemodialysis secondary to chronic renal failure. Cureus 2020;12(10):e10905. DOI: 10.7759/cureus.10905.
10. Kidney Disease: Improving Global Outcomes (KDIGO). KDIGO clinical practice guidelines for the prevention, diagnosis, evaluation, and treatment of hepatitis C in chronic kidney disease. Kidney Int Suppl 2008;(109):S1-99. DOI: 10.1038/ki.2008.81.
11. Jafar HT. The growing burden of chronic kidney disease in Pakistan. N Engl J Med 2006;354(10):995-7. DOI: 10.1056/NEJMp058319.
12. Barsoum RS. Chronic kidney disease in the developing world. N Engl J Med 2006;354(10):997-9. DOI: 10.1056/NEJMp058318.
13. Gürsoy M, Güvener N, Köksal R, et al. Impact of HCV infection on development of post-transplantation diabetes mellitus in renal allograft recipients. Transplant Proc 2000;32(3):561-2. DOI: 10.1016/S0041-1345(00)00890-3.
14. Mahmoud IM, Sobh MA, El-Habashi AF, et al. Interferon therapy in hemodialysis patients with chronic hepatitis C: study of tolerance, efficacy, and post-transplantation course. Nephron Clin Pract 2005;100(4):c133-9. DOI: 10.1159/000085442.
15. Cruzado JM, Casanovas-Taltavull T, Torras J, et al. Pretransplant interferon prevents hepatitis C virus-associated glomerulonephritis in renal allografts by HCV-RNA clearance. Am J Transplant 2003;3(3):357-60. DOI: 10.1034/j.1600-6143.2003.00057.x.
16. van der Meer AJ, Veldt BJ, Feld JJ, et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA 2012;308(24):2584-93. DOI: 10.1001/jama.2012.144878.
17. Hsu YC, Lin JT, Ho HJ, et al. Antiviral treatment for hepatitis C virus infection is associated with improved renal and cardiovascular outcomes in diabetic patients. Hepatology 2014;59(4):1293-302. DOI: 10.1002/hep.26892.
18. Gordon CE, Uhlig K, Schmid CH, et al. Long-term viral negativity after interferon for chronic hepatitis C virus infection in hemodialysis. Clin J Am Soc Nephrol 2011;6(9):2226-34. DOI: 10.2215/CJN.00410111.
19. Gupta SK, Pittenger AL, Swan SK, et al. Single-dose pharmacokinetics and safety of pegylated interferon-alpha2b in patients with chronic renal dysfunction. J Clin Pharmacol 2002;42(10):1109-15. DOI: 10.1177/009127002401382713.
20. Brennan BJ, Wang K, Blotner S, et al. Safety, tolerability, and pharmacokinetics of ribavirin in hepatitis C virus-infected patients with various degrees of renal impairment. Antimicrob Agents Chemother 2013;57(12):6097-105. DOI: 10.1128/AAC.00608-13.